Stoke Therapeutics Future Growth
Future criteria checks 2/6
Stoke Therapeutics's earnings are forecast to decline at 2.8% per annum while its annual revenue is expected to grow at 50.2% per year. EPS is expected to grow by 8.1% per annum. Return on equity is forecast to be -38% in 3 years.
Key information
-2.8%
Earnings growth rate
8.1%
EPS growth rate
| Biotechs earnings growth | 42.4% |
| Revenue growth rate | 50.2% |
| Future return on equity | -38.0% |
| Analyst coverage | Good |
| Last updated | 15 Nov 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 25 | -168 | -119 | -115 | 7 |
| 12/31/2025 | 14 | -152 | -141 | -120 | 8 |
| 12/31/2024 | 17 | -109 | -105 | -88 | 9 |
| 9/30/2024 | 17 | -105 | -85 | -84 | N/A |
| 6/30/2024 | 15 | -104 | -81 | -80 | N/A |
| 3/31/2024 | 8 | -109 | -86 | -84 | N/A |
| 12/31/2023 | 9 | -105 | -83 | -81 | N/A |
| 9/30/2023 | 9 | -103 | -85 | -83 | N/A |
| 6/30/2023 | 9 | -105 | -91 | -88 | N/A |
| 3/31/2023 | 15 | -99 | -89 | -86 | N/A |
| 12/31/2022 | 12 | -101 | -36 | -32 | N/A |
| 9/30/2022 | 9 | -100 | -30 | -26 | N/A |
| 6/30/2022 | 6 | -96 | -20 | -18 | N/A |
| 3/31/2022 | 3 | -94 | -16 | -14 | N/A |
| 12/31/2021 | N/A | -86 | -68 | -67 | N/A |
| 9/30/2021 | N/A | -76 | -63 | -62 | N/A |
| 6/30/2021 | N/A | -67 | -59 | -58 | N/A |
| 3/31/2021 | N/A | -58 | -52 | -52 | N/A |
| 12/31/2020 | N/A | -52 | -43 | -42 | N/A |
| 9/30/2020 | N/A | -48 | -43 | -41 | N/A |
| 6/30/2020 | N/A | -43 | -41 | -39 | N/A |
| 3/31/2020 | N/A | -38 | -37 | -35 | N/A |
| 12/31/2019 | N/A | -32 | -33 | -31 | N/A |
| 9/30/2019 | N/A | -26 | -26 | -24 | N/A |
| 6/30/2019 | N/A | -21 | -20 | -19 | N/A |
| 3/31/2019 | N/A | -16 | -17 | -16 | N/A |
| 12/31/2018 | N/A | -13 | -12 | -11 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 0GT is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 0GT is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 0GT is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 0GT's revenue (50.2% per year) is forecast to grow faster than the German market (5.6% per year).
High Growth Revenue: 0GT's revenue (50.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 0GT is forecast to be unprofitable in 3 years.